Literature DB >> 17915376

Enzastaurin, a targeted PKCBeta inhibitor, in relapsed or refractory DLBCL: a promising new strategy based on gene expression signature.

Carol S Portlock.   

Abstract

Entities:  

Year:  2007        PMID： 17915376

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  3 in total

Review 1.  Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach.

Authors:  Jeremy S Abramson; Margaret A Shipp
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

2.  A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.

Authors:  Auayporn Nademanee; Stephen Forman; Arturo Molina; Henry Fung; David Smith; Andy Dagis; Cheuk Kwok; Dave Yamauchi; Anne-Line Anderson; Peter Falk; Amrita Krishnan; Mark Kirschbaum; Neil Kogut; Ryotaro Nakamura; Margaret O'donnell; Pablo Parker; Leslie Popplewell; Vinod Pullarkat; Roberto Rodriguez; Firoozeh Sahebi; Eileen Smith; David Snyder; Anthony Stein; Ricardo Spielberger; Jasmine Zain; Christine White; Andrew Raubitschek
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

Review 3.  Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma.

Authors:  David J Inwards; Jeffrey C Cilley; Jane N Winter
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020
  3 in total
  1 in total

Review 1.  Management of relapsed-refractory diffuse large B cell lymphoma.

Authors:  Lalit S Raut; Prantar P Chakrabarti
Journal:  South Asian J Cancer       Date:  2014-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.